Caroline Perry

2.2k total citations · 1 hit paper
48 papers, 1.8k citations indexed

About

Caroline Perry is a scholar working on Molecular Biology, Epidemiology and Pharmacology. According to data from OpenAlex, Caroline Perry has authored 48 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Epidemiology and 11 papers in Pharmacology. Recurrent topics in Caroline Perry's work include Urinary Tract Infections Management (14 papers), Reproductive tract infections research (11 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Caroline Perry is often cited by papers focused on Urinary Tract Infections Management (14 papers), Reproductive tract infections research (11 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). Caroline Perry collaborates with scholars based in United States, United Kingdom and Germany. Caroline Perry's co-authors include Murray Stewart, B Slocombe, Deborah T. Cirkel, James William Gilbart, Nicole E. Scangarella-Oman, Étienne Dumont, David A. Wood, Christopher F. Thurston, Fred Yang and Courtney Tiffany and has published in prestigious journals such as The Lancet, Diabetes Care and Biochemistry.

In The Last Decade

Caroline Perry

47 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials

2024 44 citations Florian Wagenlehner, Caroline Perry et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caroline Perry United States	19	657	591	343	334	272	48	1.8k
Shimin Zhang United States	27	641 1.0×	118 0.2×	235 0.7×	102 0.3×	340 1.3×	82	2.0k
Shuying Li China	18	246 0.4×	185 0.3×	155 0.5×	140 0.4×	251 0.9×	56	1.1k
John Marcinak United States	19	351 0.5×	199 0.3×	684 2.0×	49 0.1×	403 1.5×	52	1.4k
Ulrich F. Schade Germany	25	657 1.0×	116 0.2×	94 0.3×	152 0.5×	593 2.2×	47	2.6k
Elena Y. Enioutina United States	24	306 0.5×	70 0.1×	190 0.6×	72 0.2×	175 0.6×	58	1.5k
Yoshiko Fukuda Japan	22	291 0.4×	92 0.2×	541 1.6×	114 0.3×	583 2.1×	63	1.5k
Paul F. Lehmann United States	27	466 0.7×	251 0.4×	995 2.9×	91 0.3×	877 3.2×	50	2.2k
Michael S. Schwartz United States	22	327 0.5×	122 0.2×	362 1.1×	375 1.1×	253 0.9×	42	1.6k
Ying‐Ju Lin Taiwan	27	800 1.2×	40 0.1×	381 1.1×	120 0.4×	263 1.0×	72	2.1k
J. D. Baumgartner Switzerland	21	424 0.6×	96 0.2×	145 0.4×	261 0.8×	905 3.3×	35	2.6k

Countries citing papers authored by Caroline Perry

Since Specialization

Citations

This map shows the geographic impact of Caroline Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Perry more than expected).

Fields of papers citing papers by Caroline Perry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Perry. The network helps show where Caroline Perry may publish in the future.

Co-authorship network of co-authors of Caroline Perry

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Perry. A scholar is included among the top collaborators of Caroline Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Perry. Caroline Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ross, Jonathan, Kimberly Workowski, Stephanie N. Taylor, et al.. (2025). Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. The Lancet. 405(10489). 1608–1620. 11 indexed citations

Scangarella-Oman, Nicole E., John Breton, D. J. Brown, et al.. (2025). Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). Antimicrobial Agents and Chemotherapy. 69(10). e0164024–e0164024. 1 indexed citations

Perry, Caroline, Shaila Shabbir, Maciej J. Zamek‐Gliszczynski, et al.. (2023). Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug–drug interactions via CYP3A metabolism and transporters. Clinical and Translational Science. 16(4). 647–661. 7 indexed citations

Wagenlehner, Flo ri an, Caroline Perry, Thomas M. Hooton, et al.. (2023). P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3). JAC-Antimicrobial Resistance. 5(Supplement_3). 2 indexed citations

Perry, Caroline, Nicole E. Scangarella-Oman, Helen Millns, et al.. (2023). Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study. Infectious Diseases and Therapy. 12(9). 2307–2320. 16 indexed citations

Hooton, Thomas M., et al.. (2023). 2832. Gepotidacin Efficacy in E. coli Drug-Resistant Phenotypes: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Scangarella-Oman, Nicole E., Mohammad Sharif Hossain, Caroline Perry, et al.. (2022). Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea. Sexually Transmitted Infections. 99(1). 64–69. 16 indexed citations

Perry, Caroline, Mohammad Sharif Hossain, Marcy Powell, et al.. (2022). Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female Participants. Infectious Diseases and Therapy. 11(6). 2297–2310. 18 indexed citations

Nguyen, Dung N., Jafar Sadik Shaik, Courtney Tiffany, et al.. (2021). Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. British Journal of Clinical Pharmacology. 88(2). 416–428. 9 indexed citations

10.

Vegvari, Carolin, Yonatan H. Grad, Peter J White, et al.. (2020). Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea. Eurosurveillance. 25(43). 8 indexed citations

11.

Nauck, Michael A., Murray Stewart, Christopher Perkins, et al.. (2015). Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 59(2). 266–274. 99 indexed citations

12.

Darpö, Börje, Meijian Zhou, Jessica Matthews, et al.. (2014). Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG Study. Diabetes Therapy. 5(1). 141–153. 23 indexed citations

13.

Watson, Julia, et al.. (2011). Apixaban. Drugs. 71(15). 2079–2089. 16 indexed citations

14.

Pollard, Jeffrey W., Caroline Perry, & Christopher F. Thurston. (2003). Northern Blotting. Humana Press eBooks. 4. 13–26. 1 indexed citations

15.

Thurston, Christopher F., Caroline Perry, & Jeffrey W. Pollard. (2003). Electrophoresis of RNA Denatured with Glyoxal or Formaldehyde. Humana Press eBooks. 4. 1–12. 1 indexed citations

16.

Simpson, Dene, Stuart Noble, & Caroline Perry. (2002). Glatiramer Acetate. CNS Drugs. 16(12). 825–850. 40 indexed citations

17.

Coleman, Ken, et al.. (1994). Bacterial resistance mechanisms as therapeutic targets. Journal of Antimicrobial Chemotherapy. 33(6). 1091–1116. 36 indexed citations

18.

Perry, Caroline, et al.. (1993). Identification of two laccase genes in the cultivated mushroom Agaricus bisporus. Journal of General Microbiology. 139(6). 1209–1218. 110 indexed citations

19.

Wu, Joseph C., Thomas C. Warren, Julian Adams, et al.. (1991). A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry. 30(8). 2022–2026. 158 indexed citations

20.

Slocombe, B & Caroline Perry. (1991). The antimicrobial activity of mupirocin—an update on resistance. Journal of Hospital Infection. 19. 19–25. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact